Megan Van Etten
Megan Van Etten is Vice President of Public Affairs. She is responsible for leading the association’s public affairs efforts on international issues, including trade, intellectual property and access to medicines. Prior to joining PhRMA, Megan was director of media and external communications at the U.S. Chamber of Commerce and communications director at the Beer Institute. She has also worked as a communications consultant for global public relations firms. When not at the office, Megan enjoys exploring new Washington, D.C. restaurants and traveling with her husband and friends.
New “America Cures” ad: U.S. patients get new medicines first
America Cures: Championing U.S. leadership in medical innovation
Americans are paying a 26% freerider tax on medicines because other countries don’t pay their fair share
Biden Administration report debunks myths around patent “evergreening” and “thickets”
What to know about the latest effort to break patents using a legally dubious avenue
WTAS: Proposed Unsubstantiated USPTO Rule Change is a Threat to American Innovation
Proposed march-in framework would chill American innovation
What they are saying: Experts agree that proposed march-in framework would jeopardize innovation
Misuse of march-in could stifle innovation
It’s PBMs, not patents, blocking competition
What you need to know: COVID-19 public health emergency is over, but ideological attacks on IP remain
WTAS on reasonable pricing and public-private partnerships
New data: America is an API powerhouse
Setting the record straight on the Bayh-Dole Act and March-in
World IP Day 2023: Celebrating women leaders in innovation
What they are saying: Experts reinforce that TRIPS waiver expansion is harmful and unnecessary
FDA-USPTO collaboration initiatives should be evidence-based, prioritize innovation
PhRMA submits comments to USPTO highlighting important role of patent system in medicine development
Expanding TRIPS waiver would jeopardize biopharmaceutical research and development
Six ways I-MAK is lying about biopharma patents
TRIPS waiver expansion risks public health
Expanding the WTO intellectual property waiver will hurt American jobs
The law driving technology transfer and fostering innovation
New report ignores benefits of patent system to innovation and patients
Partnerships are driving global COVID-19 treatment access
The dangers of expanding the TRIPS waiver
Patent policy changes proposed by USPTO and FDA would leave patients behind
ICYMI: PhRMA’s Ubl pens op-ed on IP waiver for COVID-19 technologies
Intellectual Property waiver on COVID-19 innovation is unnecessary and harmful
New Data: COVID-19 vaccine global production capacity projected to exceed 20 billion doses this year
Patients and innovators lose if the government pursues ‘march-in’
Driving further innovation is critical to global vaccine equity
Supporting country readiness to boost global vaccine access
Ensuring global vaccine equity requires eliminating trade and regulatory barriers
Increasing global access to vaccines by optimizing production
Dose sharing as a part of the COVID-19 global vaccine equity strategy
Promoting global vaccine equity while protecting innovation
IP Explained: How does the U.S. patent process work?
Supporting India during the devastating coronavirus surge
The Biden Administration allows politics to upend a pragmatic pandemic response
What they are saying: Experts highlight the importance of IP in recent NIST proposal comments
Key excerpts: PhRMA submits comments to NIST in effort to safeguard intellectual property protections
Building confidence in the COVID-19 vaccine through education
Intellectual property is the key to vaccine development, manufacturing and technology sharing
Preserving U.S. innovation worldwide is more important than ever
Manufacturing Day 2020: A closer look at the biopharmaceutical industry’s contributions
IP Explained: Intellectual property system working to combat COVID-19
On Manufacturing Day, a closer look at the biopharmaceutical sector’s contributions
Special 301 submission calls for a level playing field for American innovators
Five myths about global efforts to combat tuberculosis
Megan Van Etten